voriconazole has been researched along with End Stage Liver Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Huang, J; Li, L; Yang, Q | 1 |
| Aloia, T; Ankoma-Sey, V; Balogh, J; Boktour, M; Fainstein, V; Gaber, AO; Galati, J; Ghobrial, RM; Gordon Burroughs, S; Grimes, KA; Li, XC; McFadden, R; Monsour, HP; Ochoa, RA; Patel, S; Saharia, A; Victor, DW | 1 |
| Figiel, W; Krawczyk, M; Sulik-Tyszka, B; Wróblewska, M | 1 |
3 other study(ies) available for voriconazole and End Stage Liver Disease
| Article | Year |
|---|---|
Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study.
Topics: Adult; Antifungal Agents; Cross Infection; End Stage Liver Disease; Female; Humans; Invasive Pulmonary Aspergillosis; Itraconazole; Male; Middle Aged; Pyrimidines; Risk Factors; Survival Rate; Triazoles; Voriconazole | 2013 |
Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Cost-Benefit Analysis; End Stage Liver Disease; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Renal Replacement Therapy; Retrospective Studies; Risk Factors; Transplant Recipients; Treatment Outcome; Voriconazole; Young Adult | 2016 |
Invasive Aspergillosis of the Stomach and Co-infection With Candida krusei in a Patient With Terminal Liver Failure: A Case Report.
Topics: Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Coinfection; Echinocandins; End Stage Liver Disease; Gastric Mucosa; Humans; Lipopeptides; Liver Transplantation; Stomach Diseases; Voriconazole | 2016 |